Bilateral Multifocal Central Serous-Like Chorioretinopathy due to MEK Inhibition for Metastatic Cutaneous Melanoma.
Bilateral Multifocal Central Serous-Like Chorioretinopathy due to MEK Inhibition for Metastatic Cutaneous Melanoma.
复制标题
DOI：
10.1155/2013/673796
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
Kim SJ
中科院分区：
文献类型：
--
作者：
Schoenberger SD;Kim SJ
较新的化疗药物靶向细胞外信号传导，包括促分裂原活化蛋白激酶激酶（MEK）途径。我们报告一例54岁女性，在开始使用MEK抑制剂治疗转移性皮肤黑色素瘤后不久发生双侧多灶性中心性浆液性脉络膜视网膜病变。停药后，发现完全消退。在恢复较低剂量的MEK抑制剂后，这些发现再次复发，但在停药后消退。根据临床病程，其他病因不太可能。推测的机制涉及对视网膜色素上皮细胞的毒性，以及血液-视网膜屏障的破坏。认识到这种副作用对这种新的化疗很重要。
Newer chemotherapeutic agents target extracellular signaling, including the mitogen-activated protein kinase kinase (MEK) pathway. We present a case of a 54-year-old female who developed bilateral multifocal central serous-like chorioretinopathy shortly after starting MEK inhibition for metastatic cutaneous melanoma. There was a complete resolution of findings after drug stoppage. After resuming a lower dose of the MEK inhibitor, the findings recurred again but resolved after drug stoppage. Other etiologies were unlikely given the clinical course. The presumed mechanism involves toxicity to the retinal pigment epithelium, with breakdown of the blood-retinal barrier. Recognition of this side effect is important with this new class of chemotherapy.